1. Home
  2. MED vs PYXS Comparison

MED vs PYXS Comparison

Compare MED & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

N/A

Current Price

$11.96

Market Cap

145.0M

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

N/A

Current Price

$1.69

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MED
PYXS
Founded
1980
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.0M
141.3M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
MED
PYXS
Price
$11.96
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $8.22
AVG Volume (30 Days)
114.5K
★ 718.0K
Earning Date
10-26-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.03
EPS
N/A
★ N/A
Revenue
★ $934,842,000.00
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.22
$1.03
52 Week High
$13.63
$5.55

Technical Indicators

Market Signals
Indicator
MED
PYXS
Relative Strength Index (RSI) 42.88 40.32
Support Level $11.49 $1.29
Resistance Level $12.42 $1.77
Average True Range (ATR) 0.42 0.15
MACD -0.11 0.02
Stochastic Oscillator 4.17 43.50

Price Performance

Historical Comparison
MED
PYXS

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: